Michael Yee
Stock Analyst at Jefferies
(4.26)
# 1,038
Out of 4,479 analysts
61
Total ratings
48.72%
Success rate
18.56%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Reiterates: Buy | $125 | $117.07 | +6.77% | 6 | Apr 9, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $1.4 → $10 | $2.98 | +235.57% | 3 | Mar 27, 2024 | |
| CRGX CARGO Therapeutics | Maintains: Buy | $28 → $32 | $15.83 | +102.15% | 2 | Mar 22, 2024 | |
| IMRX Immuneering | Downgrades: Hold | $16 → $3 | $1.09 | +175.23% | 2 | Mar 15, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Hold | $40 → $45 | $41.23 | +9.14% | 1 | Dec 22, 2023 | |
| BEAM Beam Therapeutics | Downgrades: Hold | $75 → $30 | $22.57 | +32.92% | 2 | Dec 8, 2023 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $8 → $18 | $5.72 | +214.69% | 3 | Dec 8, 2023 | |
| AMRN Amarin Corporation | Downgrades: Hold | $3 → $1 | $0.71 | +41.84% | 4 | Oct 25, 2023 | |
| SRRK Scholar Rock Holding | Upgrades: Buy | $8 → $20 | $7.63 | +162.12% | 2 | Oct 25, 2023 | |
| AMGN Amgen | Reiterates: Buy | $310 | $310.77 | -0.25% | 4 | Oct 12, 2023 | |
| KOD Kodiak Sciences | Downgrades: Hold | $3 | $2.24 | +33.93% | 2 | Jul 24, 2023 | |
| ALGS Aligos Therapeutics | Upgrades: Buy | $2.5 → $3 | $0.40 | +650.00% | 1 | Jan 6, 2023 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Hold | n/a | $473.78 | - | 3 | Dec 19, 2022 | |
| BIIB Biogen | Maintains: Buy | $325 → $350 | $228.82 | +52.96% | 4 | Nov 30, 2022 | |
| VTYX Ventyx Biosciences | Initiates: Buy | n/a | $2.14 | - | 1 | Nov 15, 2021 | |
| IMCR Immunocore Holdings | Initiates: Buy | n/a | $34.80 | - | 1 | Mar 2, 2021 | |
| FGEN FibroGen | Downgrades: Hold | n/a | $0.74 | - | 2 | Mar 2, 2021 | |
| ESPR Esperion Therapeutics | Downgrades: Hold | n/a | $2.34 | - | 3 | Feb 12, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | n/a | $20.39 | - | 3 | Feb 12, 2021 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $120 | $13.35 | +798.88% | 2 | Nov 6, 2020 | |
| SDGR Schrödinger | Upgrades: Buy | n/a | $20.33 | - | 2 | Oct 12, 2020 | |
| INBX Inhibrx | Initiates: Buy | n/a | $13.56 | - | 1 | Sep 14, 2020 | |
| DNLI Denali Therapeutics | Initiates: Buy | n/a | $21.74 | - | 1 | Feb 24, 2020 | |
| AXON Axon Enterprise | Upgrades: Buy | n/a | $293.18 | - | 2 | Dec 17, 2018 | |
| URGN UroGen Pharma | Assumes: Buy | n/a | $15.14 | - | 2 | Nov 8, 2018 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $68.40 | - | 2 | Jan 26, 2018 |
Moderna
Apr 9, 2024
Reiterates: Buy
Price Target: $125
Current: $117.07
Upside: +6.77%
Nuvation Bio
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.98
Upside: +235.57%
CARGO Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $28 → $32
Current: $15.83
Upside: +102.15%
Immuneering
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.09
Upside: +175.23%
Cerevel Therapeutics Holdings
Dec 22, 2023
Downgrades: Hold
Price Target: $40 → $45
Current: $41.23
Upside: +9.14%
Beam Therapeutics
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $22.57
Upside: +32.92%
ALX Oncology Holdings
Dec 8, 2023
Upgrades: Buy
Price Target: $8 → $18
Current: $5.72
Upside: +214.69%
Amarin Corporation
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.71
Upside: +41.84%
Scholar Rock Holding
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $7.63
Upside: +162.12%
Amgen
Oct 12, 2023
Reiterates: Buy
Price Target: $310
Current: $310.77
Upside: -0.25%
Kodiak Sciences
Jul 24, 2023
Downgrades: Hold
Price Target: $3
Current: $2.24
Upside: +33.93%
Aligos Therapeutics
Jan 6, 2023
Upgrades: Buy
Price Target: $2.5 → $3
Current: $0.40
Upside: +650.00%
Vertex Pharmaceuticals
Dec 19, 2022
Downgrades: Hold
Price Target: n/a
Current: $473.78
Upside: -
Biogen
Nov 30, 2022
Maintains: Buy
Price Target: $325 → $350
Current: $228.82
Upside: +52.96%
Ventyx Biosciences
Nov 15, 2021
Initiates: Buy
Price Target: n/a
Current: $2.14
Upside: -
Immunocore Holdings
Mar 2, 2021
Initiates: Buy
Price Target: n/a
Current: $34.80
Upside: -
FibroGen
Mar 2, 2021
Downgrades: Hold
Price Target: n/a
Current: $0.74
Upside: -
Esperion Therapeutics
Feb 12, 2021
Downgrades: Hold
Price Target: n/a
Current: $2.34
Upside: -
Prothena Corporation
Feb 12, 2021
Upgrades: Buy
Price Target: n/a
Current: $20.39
Upside: -
Assembly Biosciences
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $13.35
Upside: +798.88%
Schrödinger
Oct 12, 2020
Upgrades: Buy
Price Target: n/a
Current: $20.33
Upside: -
Inhibrx
Sep 14, 2020
Initiates: Buy
Price Target: n/a
Current: $13.56
Upside: -
Denali Therapeutics
Feb 24, 2020
Initiates: Buy
Price Target: n/a
Current: $21.74
Upside: -
Axon Enterprise
Dec 17, 2018
Upgrades: Buy
Price Target: n/a
Current: $293.18
Upside: -
UroGen Pharma
Nov 8, 2018
Assumes: Buy
Price Target: n/a
Current: $15.14
Upside: -
Gilead Sciences
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $68.40
Upside: -